Journal
Diabetes Research and Clinical Practice
Publication Date
10-1-2023
Volume
204
First Page
110908
Document Type
Open Access Publication
DOI
10.1016/j.diabres.2023.110908
Rights and Permissions
Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Heerspink, Hiddo J L; McGill, Janet B; and et al., "Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial." Diabetes Research and Clinical Practice. 204, 110908 (2023).
https://digitalcommons.wustl.edu/oa_4/3093
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
